Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427338 | 1.00 | ACACB (0.45) | ACACBKMT2AEPHX1SIGMAR1MEN1 | |
| SCHEMBL12002693 | 0.94 | SIGMAR1 (0.42) | ACACBKMT2AEPHX1SIGMAR1MEN1 | |
| SCHEMBL12002499 | 0.94 | SIGMAR1 (0.42) | ACACBKMT2AEPHX1SIGMAR1MEN1 | |
| SCHEMBL196800 | 0.87 | TAAR1 (0.48) | TAAR1 | |
| SCHEMBL22236094 | 0.83 | MME (0.41) | ACACBKMT2AEPHX1SIGMAR1MEN1 | |
| SCHEMBL19342845 | 0.82 | ACACB (0.42) | ACACBKMT2AEPHX1SIGMAR1MEN1 | |
| SCHEMBL8985983 | 0.80 | TAAR1 (0.43) | KMT2AMEN1RAB9ATAAR1 | |
| SCHEMBL9148931 | 0.80 | PTGS1 (0.52) | EPHX1 | |
| SCHEMBL1336531 | 0.80 | ALDH1A1 (0.46) | MMETAAR1 | |
| SCHEMBL2298190 | 0.80 | HTR2A (0.42) | ACACBMMETAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113825748-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3225616-A1 | ALPHA-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Northwest University (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-14 | — | — | US | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | LSS, CYP51A1, BACE1 | ACACB 1071/4885KMT2A 2991/4885EPHX1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.